Category: Zacks Small Cap Research
By Lisa Thompson NASDAQ:RCRT READ THE FULL RCRT RESEARCH REPORT In Q1 Recuiter.com (NASDAQ:RCRT) continued its march to higher revenues and cash flow breakeven aided by its more than doubling of revenues and a gross margin improvement of 10.5 percent ...
By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT CPKF’s (OTC:CPKF) first quarter net earnings decreased $1.0 million, or 19%, year over year to $4.3 million, while 2022’s first quarter diluted EPS fell by $0.18, or 18%, to $0.90 f ...
By M. Marin NYSE:CXW READ THE FULL CXW RESEARCH REPORT Credit facilities underscore CXW stable revenue, strengthening balance sheet… CoreCivic (NYSE:CXW) announced new credit facilities this week, comprised of a $100 million term loan and $250 millio ...
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a California-based clinical-stage pharmaceutical company behind programs that could provide hope for the millions impacted by opioid addiction a ...
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 1Q:22 financial and operational results in a May 16, 2022 press release and filing of Form 10-Q. The materials were followed ...
By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT GBS, Inc. (NASDAQ:GBS) announced third quarter fiscal year 2022 financial and operational results for the period ending March 31, 2022 in a May 10th press release and subsequently ...
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Progressing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has two late-stage cardiometabolic programs, ARO-APOC3 and ARO-ANG3. ARO-APOC3 is ta ...
By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT Emmaus Life Sciences (OTC:EMMA) announced 1Q 2022 earnings of -$0.03 per share while revenues in the first quarter declined to $3.2 million from $5.3 million the year before. Managemen ...
By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT Since POET (NASDAQ:POET) reported Q4, not much has changed on the news front from the Q1 report. However, at its presentation at the Sidoti conference, the company gave some insight into ...